ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.03 HKD | +2.71% |
|
+13.91% | -28.54% |
| Apr. 03 | Alibaba Health Refutes Rumors of Purchase of Telemedicine Platform HaoDF | MT |
| Mar. 28 | Alibaba Health Information Technology Limited and Alibaba.com Enter Shared Services Agreement | CI |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 90,747 | 142,817 | 249,927 | 55,562 | 67,140 | 45,072 | - | - |
| Enterprise Value (EV) 1 | 90,430 | 140,292 | 238,291 | 55,562 | 56,300 | 34,160 | 32,613 | 30,855 |
| P/E ratio | -1,048 x | -19,731 x | 708 x | -209 x | 126 x | 52.9 x | 34.8 x | 24.3 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 17.8 x | 14.9 x | 16.1 x | 2.7 x | 2.51 x | 1.58 x | 1.35 x | 1.18 x |
| EV / Revenue | 17.7 x | 14.6 x | 15.4 x | 2.7 x | 2.1 x | 1.2 x | 0.98 x | 0.81 x |
| EV / EBITDA | -3,321 x | -2,546 x | 529 x | -53.7 x | 1,763 x | 61 x | 30.1 x | 19 x |
| EV / FCF | 232 x | 246 x | 246 x | 136 x | 225 x | 34.4 x | 15.7 x | 13.1 x |
| FCF Yield | 0.43% | 0.41% | 0.41% | 0.74% | 0.44% | 2.9% | 6.36% | 7.64% |
| Price to Book | 30.7 x | 26.8 x | 17.2 x | 3.93 x | 4.43 x | 2.51 x | 2.37 x | 2.14 x |
| Nbr of stocks (in thousands) | 11,700,591 | 12,063,834 | 13,477,663 | 13,507,505 | 13,511,061 | 16,081,435 | - | - |
| Reference price 2 | 7.756 | 11.84 | 18.54 | 4.113 | 4.969 | 2.803 | 2.803 | 2.803 |
| Announcement Date | 5/16/19 | 5/27/20 | 5/25/21 | 5/25/22 | 5/23/23 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5,096 | 9,596 | 15,518 | 20,578 | 26,763 | 28,506 | 33,315 | 38,114 |
| EBITDA 1 | -27.23 | -55.1 | 450.2 | -1,034 | 31.93 | 559.8 | 1,082 | 1,621 |
| EBIT 1 | -31.22 | -62.41 | 442.1 | -1,094 | -31.79 | 489.7 | 937 | 1,434 |
| Operating Margin | -0.61% | -0.65% | 2.85% | -5.32% | -0.12% | 1.72% | 2.81% | 3.76% |
| Earnings before Tax (EBT) 1 | -60.83 | 9.094 | 401.2 | -252.5 | 551 | 869.1 | 1,361 | 1,911 |
| Net income 1 | -81.95 | -6.586 | 348.6 | -265.6 | 533.4 | 766.4 | 1,139 | 1,578 |
| Net margin | -1.61% | -0.07% | 2.25% | -1.29% | 1.99% | 2.69% | 3.42% | 4.14% |
| EPS 2 | -0.007400 | -0.000600 | 0.0262 | -0.0197 | 0.0394 | 0.0529 | 0.0804 | 0.1151 |
| Free Cash Flow 1 | 390.3 | 570.1 | 967.4 | 409.4 | 250.1 | 991.6 | 2,075 | 2,357 |
| FCF margin | 7.66% | 5.94% | 6.23% | 1.99% | 0.93% | 3.48% | 6.23% | 6.18% |
| FCF Conversion (EBITDA) | - | - | 214.88% | - | 783.16% | 177.14% | 191.71% | 145.38% |
| FCF Conversion (Net income) | - | - | 277.52% | - | 46.88% | 129.39% | 182.23% | 149.41% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 5/16/19 | 5/27/20 | 5/25/21 | 5/25/22 | 5/23/23 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|
| Net sales 1 | 9,358 | 11,220 | 11,501 | 15,262 | 12,956 | 12,418 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -204.7 | - | -30.05 | -1.738 | 261.6 | 291.4 |
| Operating Margin | -2.19% | - | -0.26% | -0.01% | 2.02% | 2.35% |
| Earnings before Tax (EBT) 1 | - | - | 174 | - | 481.3 | 494.1 |
| Net income 1 | - | - | 160.7 | 372.7 | 445.9 | 349.5 |
| Net margin | - | - | 1.4% | 2.44% | 3.44% | 2.81% |
| EPS 2 | - | - | 0.0100 | 0.0275 | 0.0329 | 0.0200 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/24/21 | 5/25/22 | 11/28/22 | 5/23/23 | 11/28/23 | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 317 | 2,525 | 11,637 | - | 10,839 | 10,911 | 12,459 | 14,217 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 390 | 570 | 967 | 409 | 250 | 992 | 2,075 | 2,357 |
| ROE (net income / shareholders' equity) | -3.05% | 6.48% | 6.44% | -1.87% | 3.64% | 5.44% | 7.02% | 9.2% |
| ROA (Net income/ Total Assets) | -1.8% | -0.16% | 4.93% | -1.44% | 2.67% | 3.66% | 5.18% | 6.46% |
| Assets 1 | 4,546 | 4,032 | 7,078 | 18,471 | 19,975 | 20,962 | 21,998 | 24,413 |
| Book Value Per Share 2 | 0.2500 | 0.4400 | 1.080 | 1.050 | 1.120 | 1.120 | 1.180 | 1.310 |
| Cash Flow per Share 2 | 0.0400 | 0.0500 | 0.0800 | - | 0.0200 | 0.0700 | 0.1000 | 0.1500 |
| Capex 1 | 6.1 | 13.5 | 17.1 | 14.9 | 5.61 | 17.8 | 18.2 | 19 |
| Capex / Sales | 0.12% | 0.14% | 0.11% | 0.07% | 0.02% | 0.06% | 0.05% | 0.05% |
| Announcement Date | 5/16/19 | 5/27/20 | 5/25/21 | 5/25/22 | 5/23/23 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
2.803
CNY
Average target price
5.072
CNY
Spread / Average Target
+80.96%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -28.54% | 6.06B | |
| -29.67% | 10.84B | |
| +7.42% | 6.04B | |
| -10.39% | 5.86B | |
| -0.73% | 4.69B | |
| +52.19% | 4.29B | |
| -9.42% | 3.61B | |
| -13.25% | 3.33B | |
| -6.39% | 3.01B | |
| -2.36% | 2.8B |
- Stock Market
- Equities
- 241 Stock
- Financials Alibaba Health Information Technology Limited
